Lung Cancer Stage III Clinical Trial
Official title:
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
Primary - Evaluate safety and toxicity of AN0025 in both the consolidative setting (after chemoradiation) and in the concurrent setting (during chemoradiation) - Evaluate efficacy by progression-free survival (PFS), objective response rate (ORR), and time to death or distant metastasis (TTMD), Duration of response (DOR), Overall survival (OS) with the addition of AN0025 in both the consolidative and concurrent settings Exploratory - Evaluate pharmacokinetics of AN0025 in conjunction with chemoradiation, and then with durvalumab
The purpose of the research is to evaluate the safety and preliminary efficacy of AN0025 in combination with chemoradiation + consolidation durvalumab in advanced (Stage III) Non-Small Cell Lung Cancer. Participant will receive the experimental combination of drugs (AN0025, chemoradiation and durvalumab) and undergo laboratory tests and study procedures on specified days during the study period. Complete end of study evaluations and tests, and participate in post-study follow up every three months for two years. The time in the study will take approximately four to six hours during pre-study, study and end of study visits. Possible benefits of taking part may be improvement in your condition and slowing or stopping the growth of your cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06003075 -
Induction Chemo-Nivo in Unresectable Stage III NSCLC
|
Phase 2 | |
| Enrolling by invitation |
NCT04305613 -
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
|
||
| Not yet recruiting |
NCT05994339 -
Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06060964 -
Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management
|
Early Phase 1 | |
| Recruiting |
NCT04991025 -
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
|
Phase 2 | |
| Recruiting |
NCT06111807 -
Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
|
||
| Completed |
NCT04825912 -
Resilience Measurement in Older Adults With Late-Stage Lung Cancer
|
N/A | |
| Active, not recruiting |
NCT03141359 -
Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
|
Phase 2 | |
| Recruiting |
NCT06086574 -
Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer
|
||
| Recruiting |
NCT03872661 -
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT04364776 -
Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
|
||
| Recruiting |
NCT05258448 -
COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)
|
||
| Recruiting |
NCT05996263 -
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
|
||
| Active, not recruiting |
NCT04003246 -
Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT04057196 -
Self-System Therapy for Older Adults With Lung Cancer
|
N/A |